Copyright
©The Author(s) 2024.
World J Clin Oncol. Apr 24, 2024; 15(4): 496-522
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.496
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.496
Figure 3 Some of the current immunotherapy approaches of treatment to ovarian cancer.
Anti-CTLA-4: Cytotoxic T-Lymphocyte Associated Protein 4 Antibody; Anti-PD1: Programmed Cell death Protein 1 Antibody; Anti PD-L1: Programmed Death-ligand 1 Antibody; CAR-T cells: Chimeric Antigen Receptor-T cells; PARP: Poly Adenosine Diphosphate-Ribose Polymerase; PD-1: Programmed Cell death Protein 1; PD-L1: Programmed Death-ligand 1.
- Citation: Calmon MS, Lemos FFB, Silva Luz M, Rocha Pinheiro SL, de Oliveira Silva LG, Correa Santos GL, Rocha GR, Freire de Melo F. Immune pathway through endometriosis to ovarian cancer. World J Clin Oncol 2024; 15(4): 496-522
- URL: https://www.wjgnet.com/2218-4333/full/v15/i4/496.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i4.496